Cargando…

Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report

The resistance mechanisms to anaplastic lymphoma kinase (ALK) inhibitors comprise ALK gene variations, such as ALK point mutations and copy-number gains, the activation of bypass signaling through the activation of other oncogenes and small cell lung cancer (SCLC) transformation. To date, few studie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oya, Yuko, Yoshida, Tatsuya, Uemura, Takehiro, Murakami, Yoshiko, Inaba, Yoshitaka, Hida, Toyoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126188/ https://www.ncbi.nlm.nih.gov/pubmed/30214557 http://dx.doi.org/10.3892/ol.2018.9158

Ejemplares similares

Evaluating the diagnostic and prognostic value of serum TuM2‐PK, NSE, and ProGRP in small cell lung cancer
por: Li, Li, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

ProGRP与NSE对小细胞肺癌诊断价值的meta分析
Publicado: (2010)

血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用
Publicado: (2016)

Plasma proGRP Concentration is Sensitive and Specific for Discriminating Small Cell Lung Cancer from Nonmalignant Conditions or Non-small Cell Lung Cancer
por: Kim, Hye-Ran, et al.
Publicado: (2011)

ProGRP as early predictive marker of non–small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment
por: Kato, Yasuhiro, et al.
Publicado: (2019)

Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
por: Wojcik, Ewa, et al.
Publicado: (2017)

Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs
por: Tian, Kui, et al.
Publicado: (2022)

Detection of Changes in CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and the Relationship with CT Signs
por: Huang, Jingshan, et al.
Publicado: (2023)

Successful salvage surgery following multimodal therapy in a patient who harboured ALK‐rearranged advanced lung adenocarcinoma with multiple organ metastases
por: Horio, Yoshitsugu, et al.
Publicado: (2019)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO(2)-Au Nanocomposite
por: Wei, Zheng, et al.
Publicado: (2019)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Utility of the Serum ProGRP Level for Follow-up of Pulmonary Carcinoid Tumors
por: Taira, Naohiro, et al.
Publicado: (2014)

Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
por: Mattsson, Johanna S. M., et al.
Publicado: (2016)

Cystic brain metastases in ALK-rearranged non-small cell lung cancer
por: Marta, Guilherme Nader, et al.
Publicado: (2018)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
por: Zhao, Ruiying, et al.
Publicado: (2022)

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer
por: Kagawa, Yusuke, et al.
Publicado: (2020)

Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention
por: Xi, Chao, et al.
Publicado: (2022)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

ALK-rearrangements and testing methods in non-small cell lung cancer: a review
por: Shackelford, Rodney E., et al.
Publicado: (2014)

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer
por: Lee, Kyung Ann, et al.
Publicado: (2014)

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
por: Pan, Yue, et al.
Publicado: (2021)

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
por: Elsayed, Mei, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer
por: Wang, Zizong, et al.
Publicado: (2022)

Retracted: Effects of Bevacizumab Combined with Chemotherapy on CT, CyFRA21-1, and ProGRP and Prognosis of Lung Cancer Patients under Nursing Intervention
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
por: Nishino, Mizuki, et al.
Publicado: (2020)

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
por: Jørgensen, L. G., et al.
Publicado: (1994)

The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer
por: Xu, Liu, et al.
Publicado: (2016)

Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer
por: Doshi, Shivang, et al.
Publicado: (2016)

Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches
por: Sankar, Kamya, et al.
Publicado: (2021)

Development of a novel ALK rearrangement screening test for non–small cell lung cancers
por: Chen, Yi-Lin, et al.
Publicado: (2021)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vv0n3lk8b05prud1k6rur4q7t5